Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2021-08-30 Regulatory Filings
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Appendix 4G and Corporate Governance Statement 27 pages 455.2KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a completed Appendix 4G form, which is a key to corporate governance disclosures and a verification tool for compliance with ASX Listing Rule 4.10.3. The document includes detailed tables indicating whether the company has followed various corporate governance recommendations and where disclosures can be found, often referring to the corporate governance statement or the company's website. It explicitly states that Appendix 4G is not a substitute for the corporate governance statement and is lodged with ASX alongside the annual report. The document does not contain the full corporate governance statement itself, nor does it include financial data or management discussion. It is a regulatory filing form related to governance disclosures, serving as a compliance and verification document rather than a full report or presentation. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and content confirm it is not a brief announcement or a full annual report but a regulatory compliance filing.
2021-08-30 English
Change in substantial holding 5 pages 1.9MB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 604 Notice of change of interests of substantial holder' and references the Corporations Act 2001 Section 671B, which governs substantial shareholding notifications in Australia. It details changes in voting power and relevant interests of The Bank of New York Mellon Corporation and its group entities in Genetic Technologies Limited. The document includes specific dates of changes, voting power percentages, and annexures listing entities and changes in securities holdings. This matches the definition of a Major Shareholding Notification, which reports changes in significant share ownership levels crossing thresholds. The document is not an annual report, earnings release, or any other financial report type, nor is it a regulatory announcement or certification. Therefore, the correct classification is Major Shareholding Notification (MRQ). The document length and detail support a high confidence score.
2021-08-16 English
Completion of EasyDNA Acquisition set for global expansion 3 pages 164.8KB
M&A Activity Classification · 95% confidence The document is an announcement regarding the completion of an acquisition by Genetic Technologies Limited of EasyDNA. It details the acquisition terms, strategic rationale, and financial considerations but does not contain comprehensive financial statements or detailed financial performance data. The content focuses on the transaction and its impact on the company rather than presenting a full financial report or earnings release. Therefore, it fits best under the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2021-08-15 English
Cleansing Prospectus 22 pages 178.5KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Prospectus' and relates to an offer of new shares by Genetic Technologies Limited. It details the terms of the share offer, the purpose of the prospectus, the acquisition of EasyDNA, and the effect of the offer on the company's financial position and capital structure. The document is prepared under the Corporations Act and is intended to remove trading restrictions on shares issued pursuant to the offer. It is a transaction-specific prospectus related to a capital raising event. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not an annual or interim report, nor an announcement of a report publication. It is a detailed prospectus for a share offer and acquisition financing.
2021-08-12 English
Proposed issue of securities - GTG 6 pages 30.3KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by Genetic Technologies Limited. It details the terms of a non pro rata offer of securities under a disclosure document or product disclosure statement (PDS), including the number of securities, offer price, timetable, and regulatory compliance with ASX listing rules. There are no financial statements or detailed financial performance data present, and the document is focused on informing about the capital raising activity. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes.
2021-08-12 English
Notification of cessation of securities - GTG 4 pages 24.4KB
Regulatory Filings Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the expiry of options and convertible securities for Genetic Technologies Limited. It includes specific information about the securities that have ceased, the reasons for cessation, and the updated issued capital following these changes. The document is an announcement about changes in the company's securities, specifically the cessation of certain securities, rather than a financial report or detailed analysis. It does not contain financial statements or management discussion but is a regulatory announcement about securities status changes. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. The document length is 3832 characters, which is relatively short and consistent with an announcement rather than a full report.
2021-08-11 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.